Compare Hormel Foods Corp (HRL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Sanofi SA — how do they compare? Hormel Foods Corp trades at $24.33 (market cap $13.37B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 7.8× Hormel Foods Corp's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| HRL | SNY | |
|---|---|---|
Market Cap | $13.37B | $104.30B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $52.34 |
52-Week Low | $19.74 | $41.33 |
Enterprise Value | $15.37B | $124.19B |
Dividend Yield | 4.81% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.23, down 1.92% over 24 hours, amid a bearish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $0.40 surpassing the $0.3544 estimate. Revenue for 2025 was $12.11B, though net income margin compressed to 3.82%. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its CERATTI business in Brazil.
HRL presents a mixed outlook with a defensive profile as a consumer staple, supported by a 4.6% dividend yield. However, margin pressures and a bearish technical trend pose near-term risks. The consensus price target of $26.33 implies modest upside, but investor sentiment remains cautious given high hold ratings.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
